Your support fuels our research to #EndALS! Donate Now
Quick Info
Currently Recruiting
Trial Type
Treatment Type
Drug Trials
Start Date
Contact Information
    Contact information unknown.
Belgium, Other
Investigational Site Number :0560001, Leuven, 3000, Belgium
Canada, Alberta
Investigational Site Number :1240004, Edmonton, AB, T6G 2C8, Canada
Canada, Ontario
Investigational Site Number :1240007, Hamilton, ON, L8N 3Z5, Canada
Investigational Site Number :1240006, London, ON, N6A 5A5, Canada
Investigational Site Number :1240008, Toronto, ON, M4N 3M5, Canada
Canada, Quebec
Investigational Site Number :1240003, Gatineau, QC, J8Y 1W2, Canada
Investigational Site Number :1240002, Montreal, QC, H3A 2B4, Canada
China, Other
Investigational Site Number :1560001, Beijing, 100191, China
Investigational Site Number :1560003, Chengdu, 610041, China
Investigational Site Number :1560005, Guangzhou, 510515, China
Investigational Site Number :1560002, Hangzhou, 310009, China
Investigational Site Number :1560004, Wuhan, 430030, China
Investigational Site Number :1560006, Xi'An, 710061, China
France, Other
Investigational Site Number :2500007, Caen, 14033, France
Investigational Site Number :2500006, Lille, 59037, France
Investigational Site Number :2500002, Marseille, 13385, France
Investigational Site Number :2500003, Montpellier, 34295, France
Investigational Site Number :2500004, Tours, 37044, France
Investigational Site Number :2500005, Vandoeuvre-les-nancy, 54511, France
Germany, Other
Investigational Site Number :2760004, Berlin, 13353, Germany
Investigational Site Number :2760003, Dresden, 01307, Germany
Investigational Site Number :2760008, Haag In OB, 83527, Germany
Investigational Site Number :2760005, Hannover, 30625, Germany
Investigational Site Number :2760002, Lübeck, 23538, Germany
Investigational Site Number :2760001, Ulm, 89081, Germany
Investigational Site Number :2760009, Würzburg, 97074, Germany
Italy, Other
Investigational Site Number :3800001, Milano, 20132, Italy
Investigational Site Number :3800004, Milano, 20138, Italy
Investigational Site Number :3800002, Torino, 10126, Italy
Japan, Other
Investigational Site Number :3920005, Fuchu-shi, 183-0042, Japan
Investigational Site Number :3920004, Ichikawa-shi, 272-0827, Japan
Investigational Site Number :3920002, Koshi-shi, 861-1196, Japan
Investigational Site Number :3920003, Nagoya-shi, 466-8560, Japan
Investigational Site Number :3920001, Ota-ku, 143-8541, Japan
Investigational Site Number :3920006, Tokushima-shi, 770-8503, Japan
Netherlands, Other
Investigational Site Number :5280001, Utrecht, 3584 CX, Netherlands
Poland, Other
Investigational Site Number :6160001, Krakow, 31-503, Poland
Investigational Site Number :6160002, Ksawerow, 95-054, Poland
Spain, Other
Investigational Site Number :7240005, Barcelona, 08035, Spain
Investigational Site Number :7240002, Hospitalet de Llobregat, 08907, Spain
Investigational Site Number :7240003, Madrid, 28029, Spain
Investigational Site Number :7240001, Valencia, 46026, Spain
Sweden, Other
Investigational Site Number :7520002, Stockholm, 113 61, Sweden
Investigational Site Number :7520001, Umea, SE-901 85 Umea, Sweden
United Kingdom, Other
Investigational Site Number :8260002, Plymouth, PL6 8DH, United Kingdom
Investigational Site Number :8260003, Stoke-on-Trent, ST46QG, United Kingdom
United States, Arizona
St. Joseph's Hospital and Medical Center-Site Number:8400016, Phoenix, AZ, 85013, United States
Phoenix Neurological Associates-Site Number:8400018, Phoenix, AZ, 85018, United States
United States, California
UC San Diego Health-Site Number:8400022, La Jolla, CA, 92121, United States
USC-Site Number:8400008, Los Angeles, CA, 00000, United States
University of California Irvine-Site Number:8400012, Orange, CA, 92868, United States
California Pacific Medical Center-Site Number:8400015, San Francisco, CA, 94115, United States
United States, Colorado
University of Colorado-Site Number:8400025, Aurora, CO, 80045, United States
United States, District of Columbia
Georgetown University Medical Center-Site Number:8400020, Washington, DC, 20007, United States
United States, Florida
Mayo Clinic-Site Number:8400029, Jacksonville, FL, 32224, United States
AdventHealth Medical Group - Neurology at Winter Park-Site Number:8400006, Winter Park, FL, 32789, United States
United States, Illinois
Northwestern Medical Group, Department of Neurology-Site Number:8400003, Chicago, IL, 60611, United States
United States, Maryland
Johns Hopkins University-Site Number:8400028, Baltimore, MD, 21287, United States
United States, Massachusetts
Massachusetts General Hospital-Site Number:8400001, Boston, MA, 02114, United States
United States, New York
Mount Sinai Beth Israel Medical Center-Site Number:8400002, New York, NY, 10003, United States
United States, Pennsylvania
Penn State Milton S. Hershey Medical Center-Site Number:8400004, Hershey, PA, 17033, United States
University of Pennsylvania-Site Number:8400021, Philadelphia, PA, 19104, United States
Thomas Jefferson University Hospital-Site Number:8400014, Philadelphia, PA, 19107, United States
United States, Utah
University of Utah-Site Number:8400009, Salt Lake City, UT, 84132, United States
United States, Wisconsin
Froedtert Hospital & Medical College of Wisconsin-Site Number:8400010, Milwaukee, WI, 53226, United States
Enrollment Criteria
Breathing Ability
Percent lung function (FVC) or (SVC)
≥60% (SVC)
Months Since Onset
Number of months since first symptoms of ALS.
≤2 years
Non-Invasive Ventilation (NIV)
Can PALS use a BiPAP in the trial?
Diaphragm Pacer (DPS)
Can PALS use a DPS in the trial?
Edaravone Usage
Can a PALS use edaravone (Radicut/Radicava) while enrolled in the trial?
Open Label
Update Notes
Site updates
New site added
Protocol updates
Sites added
Completion date updated
Sites updated
Sites added
Sites added
Protocol updates
Sites removed
New sites added
New sites recruiting
Study recruiting
Study added

Other Information

This is a parallel treatment, Phase 2, randomized, double-blind study to assess the efficacy, safety, tolerability, PK, and PD of twice daily (BID) oral SAR443820 compared with placebo in male and female participants,18 to 80 years of age with ALS followed by an open label, longterm extension period. Study ACT16970 consists of 2 parts (A and B) as follows: Part A is a 24week, double blind, placebo controlled part, preceded by a screening period of up to 4 weeks before Day 1. On Day 1 of Part A, participants will be randomized in a 2:1 ratio to the SAR443820 treatment arm or matching placebo arm as listed below: Treatment arm: SAR443820, BID Placebo arm: Placebo, BID Randomization will be stratified by the geographic region of the study site, region of ALS onset (bulbar vs other areas), use of riluzole (yes vs no), use of edaravone (yes vs no) and use of the combination of sodium phenylbutyrate and taurursodiol (named Relyvrio in the United States of America [USA] and Albrioza in Canada) (yes vs no). Participants will attend in clinic study assessments at baseline (Day 1), Week 2, Week 4, Week 8, Week 16, and Week 24, and will receive a phone call at Week 12 and Week 20. All ongoing participants in Part A will rollover to part B. The Week 24 Visit is the end of Part A and the beginning of Part B. Part B is an open label, longterm extension period that starts from the end of Part A (Week 24) and continues up to Week 106. The objectives of Part B are to further determine the safety and efficacy of longterm SAR443820 treatment. The treatment assignment of participants in Part A will remain blinded to Investigators, participants, and site personnel until the end of Part B. Every participant, except those who discontinued Investigational Medicinal Product (IMP) treatment permanently in Part A , will receive BID oral tablets of SAR443820 in Part B.
Inclusion Criteria:
- Diagnosis of possible, clinically probable ALS, clinically probable laboratory supported ALS, or clinically definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria - Time since onset of first symptom of ALS ≤2 years.
- Slow Vital Capacity (SVC) ≥60% of the predicted value.
- Be able to swallow the study tablets at the screening visit.
- Either not currently receiving riluzole or on a stable dose of riluzole for at least 4 weeks before the screening visit. Participants receiving riluzole are expected to remain on the same dose throughout the duration of the study.
- Either not currently receiving edaravone or on the approved standard schedule of edaravone treatment. Participants receiving edaravone must have completed at least 1 cycle of treatment before the screening visit and are expected to continue edaravone treatment throughout the duration of the study.
- Either not currently receiving the combination of sodium phenylbutyrate and taurursodiol or on the approved standard schedule of the combination of sodium phenylbutyrate and taurursodiol treatment for at least 4 weeks before the screening visit. Participants receiving the combination of sodium phenylbutyrate and taurursodiol are expected to remain on the approved standard schedule throughout the duration of the study.
- Participants with a body weight no less than 45 kg and body mass index no less than 18 kg/m2 at the screening visit - Female participants with childbearing potential are eligible to participate if they are not pregnant or breastfeeding and agree to use adequate contraceptive method during study intervention period and for at least 32 days after the last dose of study drug.
- Male participants must agree to use highly effective contraceptive method during the study period and for at least 92 days following their last dose of the study drug.
Male participants must not donate sperms for the duration of study and 92 days after last dose of study drug.
Exclusion Criteria:
- A history of seizure (History of febrile seizure during childhood is allowed).
- Having central IV lines, such as a peripherally inserted central catheter (PICC XE ' PICC ' \f Abbreviation \t 'peripherally inserted central catheter' ) or midline or portacath lines.
- With significant cognitive impairment, psychiatric disease, other neurodegenerative disorder (eg, Parkinson disease or AD), substance abuse other causes of neuromuscular weakness, or any other condition that would make the participants unsuitable for participating in the study or could interfere with assessment or completing the study in the opinion of the Investigator.
- History of recent serious infection (eg, pneumonia, septicemia) within 4 weeks of the screening visit; infection requiring hospitalization or treatment with IV antibiotics, antivirals, or antifungals within 4 weeks of screening; or chronic bacterial infection (such as tuberculosis) deemed unacceptable as per the Investigator's judgment.
- With active herpes zoster infection within 2 months prior to the screening visit.
- A documented history of attempted suicide within 6 months prior to the screening visit, present with suicidal ideation of category 4 or 5 on the Columbia Suicide Severity Rating Scale (CSSRS) , or in the Investigator's judgment are at risk for a suicide attempt.
- History of unstable or severe cardiac, pulmonary, oncological, hepatic, or renal disease or another medically significant illness other than ALS precluding their safe participation in this study.
- Participants who are pregnant or are currently breastfeeding.
- A known history of allergy to any ingredients of SAR443820.
- Currently or previously treated with any strong or moderate CYP3A4 inhibitors or strong CYP3A4 inducers listed in Appendix 10 of the protocol within the specified washout period before the screening visit.
- Received a live vaccine within 14 days before the screening visit.
- Participants with concurrent participation in any other interventional clinical study or who have received treatment with another investigational drug (eg sodium phenylbutyrate or taurursodiol ) within 4 weeks or 5 halflives of the investigational agent before the screening visit, whichever is longer.
- Participants who have received stem cell or gene therapy for ALS at any time in the past.
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3.0 × upper limit of normal (ULN) - Bilirubin >1.5 × ULN unless the participant has documented Gilbert syndrome (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%) - Serum albumin <3.5 g/dL - Estimated glomerular filtration rate <60 mL/min/1.73 m2 (Modification of Diet in Renal Disease [MDRD]) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Part A of the study will last for 24 weeks, and participants will receive BID oral SAR443820 or placebo in a double-blind fashion for 24 weeks. All ongoing participants in Part A will rollover to Part B. Part B begins at the end of Week 24 and continues up to Week 106. All participants except those who discontinued Investigational Medicinal Product (IMP) treatment permanently in Part A will receive BID oral tablets of SAR443820 in Part B. The study duration includes an up to 4-week screening period, 24-week double blind treatment period in Part A, 80-week open label treatment period in Part B, and 2-week post treatment follow up period, with a maximum total study duration of 110 weeks.
  • Sanofi
Trial Protocol as Published on
NCT05237284 (First Published: 2/2/2022)